2024
Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (DDT): Pathways to Tumorigenesis and Therapeutic Opportunities
Valdez C, Sánchez-Zuno G, Bucala R, Tran T. Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (DDT): Pathways to Tumorigenesis and Therapeutic Opportunities. International Journal Of Molecular Sciences 2024, 25: 4849. PMID: 38732068, PMCID: PMC11084905, DOI: 10.3390/ijms25094849.Peer-Reviewed Original ResearchConceptsInhibition of MIFResponse to infectionNon-canonical signaling pathwaysClinical studiesCancer patientsClinical trialsInflammatory cytokinesDriving tumorigenesisClinical explorationCancer typesCancerDual inhibitionTherapeutic targetIn vivoIn vitroSignaling pathwayMIFAntitumor candidateBinding partners
2009
MACROPHAGE MIGRATION INHIBITORY FACTOR ANTI-THROMBIN III COMPLEXES ARE DECREASED IN BLADDER CANCER PATIENT SERUM: COMPLEX FORMATION AS A POSSIBLE MECHANISM OF MIF INACTIVATION
Meyer-Siegler K, Cox J, Leng L, Bucala R, Vera P. MACROPHAGE MIGRATION INHIBITORY FACTOR ANTI-THROMBIN III COMPLEXES ARE DECREASED IN BLADDER CANCER PATIENT SERUM: COMPLEX FORMATION AS A POSSIBLE MECHANISM OF MIF INACTIVATION. Journal Of Urology 2009, 181: 304. DOI: 10.1016/s0022-5347(09)60867-3.Peer-Reviewed Original Research
2006
Immunosuppressive Factors in Cancer
Moss J, Metz C, Bucala R. Immunosuppressive Factors in Cancer. 2006 DOI: 10.1002/3527600906.mcb.200400129.Peer-Reviewed Original ResearchImmunosuppressive factorsTumor cellsHost's antitumor defenseHost immune responseHost immune systemSuccessful cancer therapeuticsCancer patientsAntitumor defenseImmune responseEffective treatmentEvasive mechanismsImmune systemCell surface receptorsCancer therapeuticsSurface receptorsCancerCellsPatientsCytokinesProstaglandinsAntigenMajor obstacleReceptors